Coya Therapeutics Highlights Strategic Vision Under New CEO, With Key 2025 Milestones Including ALS Trial With Dr. Reddy's Partnership Worth Up To $700M, Emerging Opportunities In Parkinson's And Autoimmune Conditions, And Focus On Non-Dilutive...
Coya Therapeutics Highlights Strategic Vision Under New CEO, With Key 2025 Milestones Including ALS Trial With Dr. Reddy's Partnership Worth Up To $700M, Emerging Opportunities In Parkinson's And Autoimmune Conditions, And Focus On Non-Dilutive...
Coya Therapeutics在新任CEO的领导下强调了战略愿景，其中包括2025年的关键里程碑，包括与Dr. Reddy的合作进行的ALS试验，价值高达70000万美元，帕金森病和自身免疫疾病的新兴机会，以及关注非稀释性的战略...
Coya Therapeutics Highlights Strategic Vision Under New CEO, With Key 2025 Milestones Including ALS Trial With Dr. Reddy's Partnership Worth Up To $700M, Emerging Opportunities In Parkinson's And Autoimmune Conditions, And Focus On Non-Dilutive Funding To Advance Treg-Enhancing Biologics For Neurodegenerative And Autoimmune Diseases
Coya Therapeutics在新CEO的领导下，突出战略愿景，其中包括2025年关键里程碑，包括与Dr. Reddy's合作的ALS试验，价值高达70000万美元，深入挖掘帕金森症和自身免疫疾病的新机遇，并专注于非稀释性资金，推进用于神经退行性和自身免疫疾病的Treg增强生物制品
Dear Fellow Stockholder,
亲爱的股东：
Given my recent transition to the role of CEO, I wanted to share my thoughts on Coya and our future and to express my gratitude to our founder and Executive Chair, Dr. Howard Berman, whose bold vision has instilled the "innovation and get-it-done" culture in Coya's DNA. We...
鉴于我最近担任首席执行官一职，我想分享一下我对Coya和我们未来的看法，并对我们的创始人兼执行主席Dr...
登录免费看全文
登录/注册
资讯热榜
更新时间